In an article in the Lansing Economic Area Partnership news, Iaso was highlighted for its work with next generation of vaccines. This is an excerpt from the article written by Genesis Lodise.

A small MedTech startup in East Lansing is quietly developing the next generation of vaccines.

Iaso Therapeutics has developed a breakthrough synthetic vaccine platform that will improve health and treat a variety of diseases, including cancer and microbial infections.

The company has developed a new carrier to deliver the vaccine, faster. Iaso’s proprietary and innovative mutant Qβ (mQβ) platform technology has been shown to elicit more powerful immune responses in head-to-head comparison studies.

This new generation of vaccine technology does for sugars what mRNA vaccines did for peptides and proteins: makes it faster to adapt to emerging new threats.